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ABSTRACT
Background Single measurements of plasma Ab are not
useful in the diagnostics of Alzheimer’s disease (AD).
However, changes in plasma Ab levels during repeated
testing may be helpful in the prediction and evaluation of
progression of the incipient AD or mild cognitive
impairment.
Objective To examine the relation of baseline and serial
plasma Ab levels to cognitive change in follow-up.
Methods 269 subjects (52 cognitively impaired and 217
controls) from a population-based cohort were clinically
followed up from 3 to 6 years. Serial plasma samples
were available from 70 subjects who were followed up
for 3 years and 43 subjects followed for 6 years. The
plasma Ab levels were measured using ELISA.
Results Subjects who declined cognitively during the
follow-up had lower levels of plasma Ab42 at the
baseline. Plasma Ab42 and the Ab42/Ab40 ratio
decreased ( 2.4 pg/ml for Ab42 in 6 years) in those
who declined in follow-up, whereas Ab42 and the Ab42/
Ab40 ratio increased in the subjects who remained
cognitively stable or improved in follow-up. Subjects
using acetylsalicylic acid, dipyridamole, antidiabetic or
anticoagulant drugs as well as subjects with coronary
heart disease had higher levels of Ab40.
Conclusions Low or decreasing plasma Ab42 during
the follow-up is associated with cognitive decline. Serial
measurement of plasma Ab42 may be useful in the
detection of the subjects who are at risk for cognitive
decline.
INTRODUCTION
Alzheimer’s disease (AD) is the most common
cause of dementia. At present, its diagnosis is based
on clinical criteria and the exclusion of other causes.
However, objective biomarkers for the early diag-
nosis and monitoring of the disease process are
clearly needed because symptomatic treatments are
available, and disease-modifying drugs are already
in phase III trials. The presence of amyloid b depo-
sition in senile plaques is one pathological hallmark
of Alzheimer’s disease (AD) together with neuro-
ﬁbrillar tangles.
1 The amyloid b is a peptide
secreted by neurons
1 and platelets,
2 derived from
amyloid precursor protein APP via the activity of
proteases b and g secretase.
3 Most of the Ab
deposited in the brain is composed of 42 amino
acids (Ab42) form.
4 Ab42 has also been shown to be
ﬁrst amyloid form to accumulate with Ab40 being
deposited later in the process of AD pathogenesis.
5
The level of Ab42 in cerebrospinal ﬂuid (CSF) is
reduced in patients with mild cognitive impairment
(MCI) and AD,
67and a combination test of CSF
Ab42 and s or phospho-tau has been claimed to be
helpful in the early diagnosis of AD.
8
Ab is present in plasma, but it is still unknown
whetheritoriginatesfromperipheralsourcesorfrom
the brain. In Tg2576 transgenic mouse, plasma Ab
levels decline in parallel with their increasing accu-
mulation in the brain.
9 Since Ab can be transported
bidirectionally across the bloodebrain barrier, it has
been hypothesised that there may be an equilibrium
between CSF and plasma pools of Ab.
10 11 Seeing
that it is well established that CSF Ab42 levels
decreaseinconjunctionwiththecognitivedecline,it
has been postulated that plasma Ab42 may decrease
similarly.
12 If so, plasma Ab would offer a straight-
forward, non-invasive andeconomical biomarkerfor
AD. However, patients with known mutations in
chromosome 21 causing early-onset familial AD as
well as patients with trisomy 21 have increased
plasma Ab42 levels which are detectable before the
onset of the symptoms of dementia.
13 14 Also, the
ﬁrst-degree relatives of late-onset AD patients
exhibit elevated Ab levels measured in plasma.
15
Previous studies have suggested that the levels
of plasma Ab4 0a r ei n c r e a s e db e f o r et h eo n s e t
of sporadic AD.
16 17 However, one recent study
concluded that low plasma Ab40 level predicted AD
in older men.
18 Other studies have found elevated
Ab42 levels in patients who later develop dementia,
19
particularly in MCI amnestic type. (aMCI)
20 Finally,
several studies have not been able to detect any
signiﬁcant difference of Ab levels between AD
converters and cognitively stable controls.
21 22
ItseemsthatasinglemeasurementofplasmaAbis
not useful, whereas the change in plasma Ab levels
observed in repeated testing may be of help in the
prediction and evaluation of progression of incipient
AD or MCI.
23 However, only a limited number of
longitudinal studies have been performed.
24e26 Our
aim was to examine whether the change in plasma Ab
levels during follow-up would be more predictive of
cognitivedeclinethanstraightforwardbaselineplasma
Ab levels in a population-based cohort of MCI and
cognitively intact controls.
SUBJECTS AND METHODS
Subjects
Study subjects were participants in the population-
based study (n¼806, aged 60e76 years) examining
the risk factors and predictors of dementia in older
people
27 28 (table 1). At baseline (years 1997e1998),
52 subjects were cognitively impaired (Clinical
Dementia rating (CDR) 0.5 n¼51 and CDR 1 n¼1).
Group 1 of this study included all of the cognitively
impaired subjects from the original cohort who
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Research paperprovided a plasma sample (n¼52). For each of them, we
randomly selected 4e5 cognitively unimpaired (n¼217) age- and
sex-matched controls from the same cohort. These subjects were
clinically re-evaluated after 3 years (n¼197) and 6 years (n¼60).
The longitudinal marker group (group 2) included 70 subjects
of the original cohort of 269 subjects who provided a 3-year
follow-up plasma sample and 43 of them a 6-year follow-up
sample. Group 2 included 11 cognitively impaired (at baseline)
non-demented subjects (CDR 0.5) who provided at least one
follow-up plasma sample and 59 cognitively intact (at baseline)
age- and sex-matched controls with at least one follow-up
plasma sample (ﬁgure 1). Drop-outs occurred mainly due to
a refusal of the participants to continue the study. Written
informed consent was obtained from all the subjects, and the
study was approved by the local Ethical Committee.
Clinical evaluation
The evaluation included a structured detailed interview
including demographic information, medical history, medica-
tion, smoking habits and alcohol consumption, and a subjective
assessment of memory disturbances and depression. The evalu-
ation also included clinical examination as well as an assessment
of cognitive impairment by applying the CDR and using
a battery of neuropsychological tests: Memory: Visual Repro-
duction Test from Wechsler Memory Scale,
29 Word List Recall
from the CERAD Neuropsychological Assessment Battery,
30
Logical Memory Test from Wechsler Memory ScaledRevised,
31
NYU Paragraph Recall,
32 Delayed Recall of the Constructional
Praxis from CERAD;
30 Language: vocabulary subtest from the
Wechsler Adult Intelligence Scale-Revised,
33 Abbreviated (15
items) Boston Naming Test;
34 Attention and executive function:
Trail Making Test
35 parts A and B, Verbal Fluency Test;
36 37
Visuospatial skills: Block Design from the WAIS-R,
33
Constructional Praxis from CERAD;
30 Global functioning: Mini-
Mental State Examination
38 (MMSE) Clock Drawing Test.
30
Cognitive decline was deﬁned by the CDR change from 0 to
0.5 or 0.5 to 1.
Measurement of Ab40 and Ab42
The 269 baseline samples (group 1) were measured in year
2002e2003. After completing the 6-year follow-up, we rean-
alysed the baseline samples of 70 subjects (group 2) together
with their follow-up samples in year 2006e2007 (group 2).
A venous blood sample was obtained into heparin tubes, and
plasma was separated using standard methods. The samples
were aliquotted and stored in polypropylene tubes at  708C
until analyses. Ab40 was measured by the ELISA method
modiﬁed from a well-established method.
16 The capture anti-
body was 6E10 (Sigma, St Louis, Missouri), and the detection
antibody was a biotin-labelled G2-10 antibody (The Genetics
Company, Schlieren, Switzerland). The synthetic Ab1e40 peptide
(Bachem, Bubendorf, Switzerland) was used as the standard.
Before the analyses, 0.05% Tween 20e0.5% BSA was added to
the samples. Ab42 was measured by a high-sensitivity method
of a commercially available ELISA (Innogenetics, Gent, Belgium)
which we modiﬁed to be suitable for the measurements of
concentrations higher than 7 pg/ml. Before the analyses, 0.5 M
guanidine chloride was added to the standards and samples. The
detergents were used to avoid coagulation of samples and to
release Ab peptides from plasma proteins.
In a longitudinal analysis, baseline and follow-up samples
from one individual were placed on the same plate to prevent
interassay variation. Thus, we measured baseline samples from
70 subjects twice (4 years apart). The absolute concentrations
differed between these two measurements; median level for
Ab40 174.5 (year 2003) and 198 pg/ml (74) (year 2007), and
Ab42 17 (year 2003) and 49 pg/ml (110) (year 2007). However,
there was a moderately good correlation between these
measurements (Ab40 r¼0.674, p<0.001 and Ab42 r¼0.824,
p<0.001). The correlation ﬁgure is presented in the supple-
mental data (available at http://www.jnnp.com).
The interassay variation for the Ab40 assay was 23.8% and for
the Ab42 assay 19.1%. The inter-CVs were measured using
reference samples of medium concentration (w250 pg/ml for
Ab40 and w400 pg/ml for Ab42). The intra-assay variations for
Ab40 were 0.71% for high (w1200 pg/ml), 0.95% for medium
and 5.9% for low concentrations (w150 pg/ml). The intra-assay
POPULATION-BASED COHORT
Random sample of 1,150 subjects
806 subjects evaluated
GROUP 1
269 provided a 
plasma sample at baseline
GROUP 2
70 provided a follow-up 
plasma sample
N = 70
Clinical follow-up and plasma
sample – 3 years
N = 43
Clinical follow-up and plasma
sample – 6 years
N = 197
Clinical follow-up
– 3 years
N = 60
Clinical follow-up
– 6 years
Figure 1 Formation of the study population.
Table 1 Baseline demographic information of the subjects
Population-based
cohort
Group 1 (cognitive
follow-up)
Group 2 (plasma
follow-up)
n 806 269 70
Age 68 (60e76) 70 (60e77) p>0.1 71 (61e77) p>0.1
Men/women 321/485 47%/53% 121/148 45%/55% p>0.1 25/45 36%/64% p>0.1
APOE e4  /+ 414/207* 67%/33% 169/99y 63%/37% p>0.1 37/33 53%/47% p>0.05
Mini-Mental State Examination 26 (7e30) 27 (13e30) 26 (17e30)
CDR¼0 731 217 59
CDR¼0.5 70 51 11
CDR¼1z 31 0
Data are given as median values (range) or as number of subjects with the percentage of all subjects in the group.
*APOE data missing from 185 subjects.
yAPOE data missing from one subject.
zOne subject had CDR 2. Data missing from one subject.
CDR, Clinical Dementia rating.
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Research paperCVs (median) for Ab42 were 1.6% (w1000 pg/ml), 2.5% and
9.8% (w15 pg/ml), respectively.
APOE genotyping
The APOE allele genotyping was done by a PCR-based
method.
39 The subjects were subdivided into the APOE e4
negative and APOE e4 positive subjects.
Statistics
The statistical analyses were conducted using SPSS for Windows
release 14.0.1 (SPSS, Chicago, Illinois). Due to the non-normal
distribution of data, Kruskal Wallis, ManneWhitney U and
Spearman correlation tests were used. The categorical data were
analysed by the c
2 test. The ORs for cognitive decline of
patients in different groups were calculated by logistic regression
analysis. We ﬁtted a linear regression slope by Microsoft Excel to
analyse the alteration trend of Ab levels.
RESULTS
Table 1 presents the demographic information about the
subjects. The baseline Ab40 and Ab42 levels of 269 individuals
were generally low, although some subjects exhibited extremely
high Ab42 levels. The limit for the 90th percentile was 101 pg/
ml, but the highest measured level was 1341 pg/ml. The Ab40
levels showed a weak correlation with age (r¼0.186, p¼0.002),
but this was not the case with the Ab42 levels. There were no
differences in Ab40 and Ab42 levels between the sexes or
between the APOE e4 carriers and non-carriers. Ab42 levels did
not correlate with Ab40 concentrations.
Baseline Ab levels and cognitive decline during the follow-up
No signiﬁcant differences were found in plasma Ab40, Ab42 or
the Ab42/Ab40 ratio between cognitively impaired (n¼52) and
cognitively intact subjects (n¼217) at baseline.
However, 197 of these subjects were clinically assessed after
3 years, and 60 were clinically assessed after 6 years. The baseline
Ab42 levels were signiﬁcantly lower in the subjects who showed
cognitive decline after 3 years of follow-up (cognitively stable,
n¼147: 19 pg/ml (0e1341), cognitive decline, n¼50: 12 pg/ml
(0e276), p¼0.001). Baseline Ab42 levels were also lower in
subjects who had declined cognitively after 6 years (10 pg/ml,
n¼36) compared with those who remained cognitively stable
(18 pg/ml, n¼24), p¼0.013.
Subjects who had baseline Ab42 levels in the lowest quartile
displayed an OR of 3.12 (95% CI 1.25 to 7.79, p¼0.015) for
cognitive decline after 3 years and 4.77 (95% CI 1.14 to 19.98,
p¼0.033) after 6 years in comparison with subjects who had
Ab42 levels in the highest quartile. Similarly, subjects who had
an Ab42/Ab40 ratio in the lowest quartile had an OR of 3.26
(1.31 to 8.11, p¼0.011) for cognitive decline after 3 years and
8.40 (1.83 to 83.568, p¼0.006) after 6 years of follow-up when
compared with the subjects in the highest quartile.
Relationship between changing plasma Ab levels and cognitive
decline
The follow-up plasma samples were available from 70 subjects
after 3 years and 43 subjects after 6 years of follow-up. The
median levels of Ab42 did not change or decreased in subjects
with cognitive decline (n¼27 after 3 years and n¼14 after
6 years), whereas they increased in those who remained cogni-
tively stable (table 2). No statistically signiﬁcant changes were
found in Ab40 levels. The Ab42/Ab40 ratio decreased signiﬁ-
cantly in the subjects who experienced a cognitive decline.
A trend analysis was undertaken by calculating a slope for
each subject, and this was used to assess the change of Ab42
between cognitively stable and cognitively declining subjects.
During the follow-up of 3e6 years, the cognition of 28 out of
the total 70 subjects had declined, and there was a decreasing
trend in the level of Ab42 in 24 subjects during the follow-up.
The Ab42 level remained the same in the declining subjects and
increased in the cognitively stable subjects (0.0 (4.9) pg/ml/year
and 2.1 (21) pg/ml/year; p¼0.009 for slope difference). The
corresponding changes of Ab42/Ab40 ratio were also signiﬁcant
(0.0 (0.029) per year and 0.0036 (0.055) per year; p¼0.02 for
slope difference).
Plasma Ab and general health
Table 3 shows the relationship between medication as well as
certain diseases on the plasma Ab levels. The Ab40 levels were
not associated with the use of lipid-lowering drugs or non-
steroidal anti-inﬂammatory drugs (NSAIDs) at baseline.
Hormone-replacement therapy was not related to Ab values in
women. The Ab40 levels were higher in those subjects using
acetylsalicylic acid (ASA) (n¼62, p¼0.004) or dipyridamole
(n¼12, p¼0.017). The Ab40 values were lowest in subjects using
neither of the drugs, intermediate in subjects using either ASA or
dipyridamole and highest in the subjects taking both drugs. The
Ab40 levels were also higher in subjects using insulin alone
(n¼5, p¼0.009) or insulin in combination with oral antidiabetic
drugs (n¼13, p¼0.003). The Ab42 levels were not associated
with the use of any of the drugs. Coronary heart disease was
associated with a high plasma Ab40 level (p¼0.035). There was
Table 2 Cognition and changes of Ab between baseline and follow-ups in subjects
Baseline Cognitively healthy Cognitively impaired
N5 9 1 1
Ab40 195 (88) 201 (60)
Ab42 50 (121) 46 (92)
Ab42/Ab40 0.236 (0.464) 0.291 (0.487)
Cognitively stable or improved Cognitive decline
Follow-up 3 years 6 years 3 years 6 years
N4 3 y 29z 27 14
Change of Ab40 18 (55) 33 (45) 21 (24) 33 (75)
Change of Ab42 3.7 (29) 12 (54) 0.0 (14)*  2.4(50)*
Change of Ab42/Ab40 0.0093 (0.169) 0.0166 (0.451)  0.0027 (0.084)*  0.0486 (0.251)*
Data are given as medians (IQR). The values of p reﬂect the signiﬁcance against the cognitively stable subgroup.
*p<0.05 against ‘stable or improved.’
yAb data of one subject is from a plasma sample of 4 years of follow-up.
zCognition data of two subjects is from the previous year.
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the cognitively stable and the cognitive decliners.
DISCUSSION
Our results indicated that low or decreasing plasma Ab42 levels
and Ab42/Ab40 ratio were related with cognitive decline during
the follow-up. Moreover, a possible age-related increase in
plasma Ab42 levels in serial measurements was associated with
stable cognitive performance.
We found no differences in plasma Ab levels between cogni-
tively intact and impaired subjects in the cross-sectional analysis
at baseline. Previous cross-sectional studies comparing plasma Ab
levels in patients with sporadic AD and controls have reported
contradictory results. Elevations of plasma Ab40
16 or Ab42
19
have been described, whereas other studies have found no
differences between AD and controls.
21 One recent study found
increased levels of plasma Ab42 in women with amnestic MCI
compared with healthy controls or affected men.
40 However, low
Ab42 levels at baseline were associated with a cognitive decline
occurring during the follow-up. In line with our results, a recent
study detected an association between a low Ab42/Ab40 ratio
and cognitive decline.
12 Respectively, a prospective three-city
study of 257 dementia patients found an association of high
Ab42/Ab40 ratio with a lower risk of dementia in follow-up.
41
Another population-based case-cohort study claimed that indi-
viduals witha combination of lowAb42 andhigh Ab40measured
from plasma at baseline had more than a 10-fold risk of dementia
but found no association between the Ab42 or Ab40 levels alone
with cognitive decline.
17 Other studies have reported different
results. The VITA study found no association between baseline
Ab levels and cognitive decline during the follow-up. Other
studies have found elevated concentrations of Ab42 at the base-
line in subjects who developed AD during the follow-up,
19 42
although plasma Ab levels were not associated with AD in the
fully adjusted multivariate model.
42
Differences in study cohorts, for example timing with respect
to cognitive decline, assessment of cognitive functioning
(different tests) and presence of confounding factors such as
medication and other diseases, are all factors that can inﬂuence
the results. The outcome in some studies has been conversion to
dementia,
17 19 whereas the outcome in our study as well as in
some other studies
12 was cognitive decline. The difference in the
selected outcome and the timing of the sample collection may
partially explain differences in the results.
Single measurement of plasma Ab may not be a suitable
marker for AD due to many confounding factors. The timing of
the Ab measurement in terms of the natural history of AD may
be critical. Experimental studies on transgenic animals suggest
that plasma Ab levels decrease at the time when accumulation
of Ab begins in the brains.
9 It is possible that the increased
plasma Ab concentration is related to the development of AD as
suggested by the ﬁndings of elevated plasma Ab levels in AD
gene mutation carriers
43 and in the ﬁrst-degree relatives of the
patients with late-onset AD.
15 However, since amyloid
pathology in the brain begins years before the appearance of the
ﬁrst symptoms, the possible increase in plasma Ab may not be
detected in the symptomatic individuals. This hypothesis can
only be addressed in longitudinal studies. In line with our
results, previous studies have suggested that decreasing Ab levels
are associated with cognitive decline,
19 24 and Ab42 levels were
lower in patients diagnosed having AD than in those with
MCI.
44 Many studies have shown that plasma Ab levels increase
with age, as was found in the cognitively intact subjects in our
study.
19 25 42 In one study, the age-related increase was smallest
in those subjects who converted to AD from MCI.
25 It is
possible that age-related changes of plasma levels of Ab40 and
Ab42 differ in subjects with AD. In this respect, the Ab42/Ab40
ratio may be a better predictor for AD than the single markers.
Differences in study cohorts make the comparison between
different studies difﬁcult. There are many confounding factors
that may inﬂuence plasma Ab levels. Renal dysfunction may
increase plasma, since plasma Ab is excreted through the
kidneys.
45 Many studies have suggested an association between
vascular disease and plasma Ab levels.
46e48 The levels of plasma
homocysteine, a possible marker for vascular disease, correlate
positively with plasma Ab40 and Ab42 levels.
49 Previous studies
have also suggested that certain drugs may inﬂuence plasma
Ab.
50 We found elevated levels of Ab40 in the subjects who were
using ASA and dipyridamole, that is drugs that directly inﬂuence
platelet function and activation, and subjects who used anti-
coagulation and antidiabetic drugs, whereas there was no asso-
ciation between the use of NSAIDs or lipid-lowering agents and
plasma Ab levels. The association between ASA and plasma
Ab40 was seen also in subjects without cardiovascular diseases.
In line with previous studies,
50 51 no relationship was found
between Ab levels and lipid-lowering agents in previous studies.
Differences in methodology and experimental conditions may
also inﬂuence results. Erythrocytes and plasma proteins, for
example albumin and lipoproteins, bind Ab and denaturating
conditions liberate Ab into the free pool of plasma.
52 Also, the
different antibodies used in the immunological assays may
detect different fractions of Ab. Previous studies suggested that
the absolute levels of Ab vary across different ELISA batches.
53
We also noticed a difference between absolute levels in 70
samples that were measured twice 4 years apart. Because of
these methodological difﬁculties, the diagnostic value of a single
measurement is limited.
The signiﬁcance of the standardisation of the conditions in
storing and handling the samples is reported in a study by
Vanderstichele et al.
22 To better utilise these analyses, the assays
used should be commercially available, well standardised and
thoroughly validated.
We conclude that plasma Ab is not a diagnostic marker for
AD, but the decreasing levels of Ab42 in serial measurements
may be associated with cognitive decline and indicate the
development of AD.
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Table 3 Relation of Ab40 level to medication at baseline
Group 1 pg/ml pg/ml
nA b40 Users Non-users
Sex, female 148 e
Smoking 21 e
Coronary heart disease 61 [ p¼0.035 188 (105e360) 176 (0e780)
Diabetes 22 e
Anticoagulants 16 [ p¼0.038 198 (144e360) 176 (0e780)
Non-steroidal
anti-inﬂammatory drugs
22 e
Acetylsalicylic acid 62 [ p¼0.004 194 (0e278) 175 (0e780)
Dipyridamole 12 [ p¼0.016 208 (156e278) 176 (0e780)
Antidiabetics* 13 [ p¼0.003 219 (161e426) 179 (0e780)
Lipid-lowering agents 24 e
*Insulin and oral antidiabetics.
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